Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Clinical trial NCT04737928 · COMPLETED
Trial details
- NCT number
- NCT04737928
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-02
- Primary completion
- 2019-01-22
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.